Home About Us Writing a Scientific Article Author's Instruction Contact us



/  /    MRJMMS Home   /   /    About MRJMMS    /  /    Submit Manuscripts    /  /      Call For Articles      / /     Editorial Board     / /    Archive     / /    Author's Guide  /  /


December 2016 Vol. 4 No.12

Other viewing option

• Full text
Reprint (PDF) (314 KB)

Search Pubmed for articles by:

Khedr R
Sheta F

Other links:
PubMed Citation
Related articles in PubMed



Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 4(12) pp. 511-518, December, 2016 

Copyright © 2016 Merit Research Journals

Original Research Article

Docetaxel plus androgen deprivation therapy as first –line treatment in high volume metastatic hormone-sensitive prostate cancer


Rasha Abd El-Ghany Khedr* and Mohamed Fathy Sheta


Clinical Oncology Department Faculty of Medicine-Tanta University, Tanta, Egypt

*Corresponding Author’s E-mail: Khedr_rasha@yahoo.com
Tel.: 01227939561

Accepted December 09, 2016




Addition of docetaxel to androgen deprivation therapy (ADT) as first –line treatment in high volume metastatic hormone-sensitive (hormone naïve) prostate cancer (mHSPC). The Sun sets on ADT alone in mHSPC after the results of CHAARTED trial and STAMPEDE trial, that showed significant improvement in overall survival after addition of docetaxel to ADT in comparison to ADT alone. From January 2012 to January 2014, 46 patients with newly diagnosed metastatic hormone sensitive prostate cancer with confirmed measurable high-volume metastatic disease, were enrolled Eligible. Patients received androgen-deprivation therapy (with a long-acting GnRH agonist (Goserelin acetate, 3.6 mg subcutaneously monthly) and an androgen antagonist (Flutamide®, 750 mg daily) plus docetaxel (at a dose of 75mg/m2 given as an intravenous infusion every 3 weeks × 6 cycles). The median follow up period was 49 months ± SE 4.905 Median progression free survival (PFS) was 28 months ± SE 1.787. The 2-year PFS rate was 58.6%. Median overall survival (OS) was 49 months ± SE 4.905. The 2-year OS rate was 85.9%. Docetaxel in addition to ADT should be considered SOC for men with newly diagnosed mHSPC.

Keywords: Androgen deprivation therapy, Docetaxel, Metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer, Taxanes





Merit Research Journals© 2016 || Advertisement | Privacy policy.